CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Velaglucerase alfa

Last Updated: October 28, 2010
Result type: Reports
Project Number: SR0215-000
Product Line: Reimbursement Review

Generic Name: Velaglucerase alfa

Brand Name: VPRIV

Manufacturer: Shire Human Genetic Therapies

Therapeutic Area: Gaucher Disease

Indications: Gaucher Disease

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 25, 2011

Recommendation Type: List with clinical criteria and/or conditions